Recent work showed that tamoxifen activates the estrogen (G-protein-coupled) receptor (GPER) on breast cancer-associated fibroblasts, promoting proliferation and cell cycle progression through the GPER/EGFR/ERK axis. This evidence concerns the gene EGFR and breast cancer.